MindMed is a biopharmaceutical company focused on medicines to alleviate suffering and improve mental health and the first pure play psychedelics company to be publicly traded with their March 2020 listing on the NEO Exchange. This report provides an overview of MindMed’s business, research, and activities to date.
The Report covers every key element of the sector you need to know about to understand and identify opportunity in the space.
- Therapeutic Pipeline: An overview of the substances MindMed is developing and the progress they’ve made.
- Financings and Public Listing: A review of the multiple investment rounds conducted by the company along with their public listing.
- Key Acquisitions and Partnerships: Highlights of the key deals which are paving the way for MindMed’s growth.
- Team: Who are the key players involved in MindMed, and how they’ll contribute to the company’s success.
Download your copy of The Report on Psychedelics Case Study: Mind Medicine Inc. The Report is provided free thanks to the support of the Neo Exchange.
Sponsored by:
